Bayer Draws a Higher Berenberg Target but No Upgrade as Drug Approvals Reshape the Story
Published on 11/18/2026 at 11:51 | Editorial boerse-global.deBerenberg has raised its price target on Bayer from EUR 53.50 to EUR 62 while keeping its rating at "Hold" — a distinction that matters more than it might first appear. The broker is lifting its valuation benchmark, not turning buyer. Analyst Sebastian Bray credits momentum in the pharmaceuticals business for the more optimistic assessment, but stops short of a buy recommendation.
The nuance is sharpened by the stock's run: Bayer has climbed 54% since the start of the year. A higher target paired with an unchanged neutral stance reads as a more favorable view of what the company is worth, not a shift into the bull camp.
A Monsanto IPO as a Long-Term Funding Lever
Bray also floated a structural idea with a long horizon — a possible stock market listing of Monsanto toward the end of the decade. Proceeds from such a move could then be channeled into pharmaceutical development, linking a potential change in group structure to fresh capital for the drug business.
The subjunctive carries the weight here. Bray is describing a strategic option, not a decided spin-off or IPO, and offers no near-term date against which investors could measure execution. It belongs in the realm of long-term valuation scenarios rather than a scheduled event.
Should investors sell immediately? Or is it worth buying Bayer?
Third-Quarter Figures as the Reality Check
On the operating side, revenue growth and an improvement in earnings per share sit side by side. Bayer posted third-quarter 2026 sales of EUR 10.05 billion, up from EUR 9.66 billion a year earlier.
Reading the Berenberg note properly requires separating the performance of the whole group from the pharma momentum the analyst explicitly highlights — the headline figures alone do not quantify what the drug business contributed. Earnings per share remained negative at ?0.69 euros in the same quarter, an improvement from ?0.98 euros a year prior. The per-share loss narrowed but did not disappear.
The next scheduled data point is the fourth-quarter report on 24 February 2027. Until then, the takeaway from the analysis is straightforward: Berenberg sees more value in Bayer, yet after the stock's strong year it still treats the shares as a hold.
Two Approvals and a Raised Outlook
The pharma pipeline has meanwhile delivered regulatory wins that give the bulls something to work with. On 10 November the US Food and Drug Administration cleared Asundexian to reduce the risk of recurrent strokes, used alongside antiplatelet therapy. According to Bayer, it is the world's first approved factor XIa inhibitor.
In China, Sevabertinib won approval on 4 November as a first-line treatment for patients with HER2-mutated non-small cell lung cancer. Bayer said the decision rests on the ongoing Phase I/II SOHO-01 trial.
Bayer at a turning point? This analysis reveals what investors need to know now.
A day earlier, on 3 November, the group had raised its outlook for the Pharmaceuticals margin, for group EBITDA before special items and for free cash flow, while projecting lower net financial debt.
A Wide Spread of Analyst Views
Opinion on the stock is anything but uniform. Price targets from Deutsche Bank Research and Jefferies span EUR 48.50 to EUR 65. Deutsche Bank lifted its target to the top of that range from EUR 60 on 10 November and reaffirmed its buy rating. Jefferies, on the same day, stuck with "Hold" and a target at the bottom of the range.
The shares slipped 1.4% yesterday to close at EUR 56.02 — squarely between those two markers, and with Berenberg's freshly raised EUR 62 now sitting above the market price.
Ad
Bayer Stock: New Analysis - 18 November
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
